Vanguard Group Inc. Acquires 47,432 Shares of Charles River Laboratories International, Inc. $CRL

Vanguard Group Inc. boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,887,175 shares of the medical research company’s stock after acquiring an additional 47,432 shares during the quarter. Vanguard Group Inc. owned 0.12% of Charles River Laboratories International worth $1,174,374,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Charles River Laboratories International by 1.0% in the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock worth $195,446,000 after acquiring an additional 12,035 shares during the period. Bank of America Corp DE raised its stake in shares of Charles River Laboratories International by 13.4% during the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after purchasing an additional 137,335 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Charles River Laboratories International by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after purchasing an additional 120,207 shares in the last quarter. Earnest Partners LLC lifted its holdings in Charles River Laboratories International by 0.8% during the 3rd quarter. Earnest Partners LLC now owns 1,006,724 shares of the medical research company’s stock worth $157,512,000 after purchasing an additional 8,467 shares in the last quarter. Finally, National Bank of Canada FI boosted its stake in Charles River Laboratories International by 117.7% in the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after purchasing an additional 511,901 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.6%

Shares of CRL opened at $165.92 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $113.89 and a 1-year high of $228.88. The company has a market capitalization of $8.19 billion, a P/E ratio of -56.05, a P/E/G ratio of 2.02 and a beta of 1.45. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The firm’s 50 day simple moving average is $169.78 and its 200 day simple moving average is $182.99.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the subject of a number of recent analyst reports. Barclays lifted their target price on Charles River Laboratories International from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Robert W. Baird set a $193.00 target price on shares of Charles River Laboratories International in a research note on Thursday, February 19th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.36.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.